NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. 

Burford Capital Limited (OTCMKT: BRFRF, BRFRY)
Class Period: March 18, 2015 - August 7, 2019
Deadline: October 21, 2019
For more info: www.bgandg.com/brfrf
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Burford has been manipulating its metrics, including ROIC and IRR, to create a misleading picture of investment returns to investors; (2) these manipulations hid the fact that the Company is at high risk for a liquidity crunch and is already arguably insolvent; and (3) as a result of the aforementioned misconduct, Defendants’ statements about Burford’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Class Period: September 6, 2017 - August 19, 2019
Deadline: October 29, 2019
For more info: www.bgandg.com/srpt
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) golodirsen posed significant safety risks to patients; (2) consequently, the NDA package for golodirsen’s accelerated approval was unlikely to receive FDA approval; and (3) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.

Canada Goose Holdings Inc. (NYSE: GOOS)
Class Period: March 16, 2017 - August 1, 2019
Deadline: November 4, 2019
For more info: www.bgandg.com/goos
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Canada Goose sourced the down and fur used in its clothing products in a way that treated animals in an unethical and inhumane manner; (2) Canada Goose was thus non-compliant with relevant FTC regulations pertaining to false advertising with respect to its sourcing practices; (3) accordingly, Canada Goose was the subject of an ongoing FTC investigation regarding false advertising; and (4) consequently, the Company’s public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.